Short Interest in PURE Bioscience (OTCMKTS:PURE) Increases By 155.8%

PURE Bioscience (OTCMKTS:PURE) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totaling 26,140 shares, an increase of 155.8% from the November 30th total of 10,219 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 105,877 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 105,877 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the shares of the stock are short sold.

PURE Bioscience Trading Up 0.6%

Shares of OTCMKTS:PURE traded up $0.00 during mid-day trading on Friday, reaching $0.05. The stock had a trading volume of 7,236 shares, compared to its average volume of 54,961. The business’s 50 day moving average price is $0.06 and its 200 day moving average price is $0.07. PURE Bioscience has a 1 year low of $0.04 and a 1 year high of $0.21. The company has a market cap of $5.21 million, a P/E ratio of -1.55 and a beta of 0.51.

PURE Bioscience (OTCMKTS:PURE) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business had revenue of $1.71 million during the quarter.

About PURE Bioscience

PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions.